Evidence syntheses — page 4
140 structured review questions, each with a registered PICO frame, a reproduced search, an included-studies table, a summary of findings and an amendment log.
Reviews
-
In the population defined for type 2 diabetes mellitus, is the effect of Lixisenatide maintained across the full duration of the contributing trials?
High03 Feb 2026 -
In the population defined for type 2 diabetes mellitus, what is the effect of Lixisenatide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
High01 Nov 2024 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Lixisenatide compared with its comparator?
High31 May 2026 -
In the population defined for type 2 diabetes mellitus, is the effect of Orforglipron maintained across the full duration of the contributing trials?
Moderate21 Apr 2026 -
In the population defined for type 2 diabetes mellitus, what is the effect of Orforglipron compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Moderate15 Feb 2026 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Orforglipron compared with its comparator?
Moderate05 May 2026 -
In the population defined for obesity and overweight in adults, is the effect of Survodutide maintained across the full duration of the contributing trials?
Moderate10 May 2026 -
In the population defined for obesity and overweight in adults, what is the effect of Survodutide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Moderate05 Sep 2026 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Survodutide compared with its comparator?
Moderate15 Jul 2025 -
In the population defined for immune modulation and adjunctive immunotherapy, is the effect of Thymosin alpha-1 maintained across the full duration of the contributing trials?
Moderate26 Aug 2026 -
In the population defined for immune modulation and adjunctive immunotherapy, what is the effect of Thymosin alpha-1 compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Moderate09 Jun 2026 -
Thymosin alpha-1 in immune modulation and adjunctive immunotherapy: tolerability and discontinuation
In the population defined for immune modulation and adjunctive immunotherapy, what is the incidence of adverse events leading to discontinuation with Thymosin alpha-1 compared with its comparator?
Moderate30 Mar 2025 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, is the effect of Exenatide maintained across the full duration of the contributing trials?
High25 Jun 2026 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the effect of Exenatide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
High29 Jan 2026 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the incidence of adverse events leading to discontinuation with Exenatide compared with its comparator?
High07 Jan 2026 -
In the population defined for obesity and overweight in adults, is the effect of Liraglutide maintained across the full duration of the contributing trials?
High15 Nov 2025 -
In the population defined for obesity and overweight in adults, what is the effect of Liraglutide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
High20 Aug 2026 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Liraglutide compared with its comparator?
High11 Mar 2026 -
In the population defined for obesity and overweight in adults, is the effect of Mazdutide maintained across the full duration of the contributing trials?
Moderate18 Aug 2025 -
In the population defined for obesity and overweight in adults, what is the effect of Mazdutide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Moderate18 Jul 2026
page 4 of 7